We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Avg Time Held
3.5
quarters
Top 10 Avg Time Held
1.6
quarters
Top 20 Avg Time Held
2.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Caris Life Sciences
CAI
$8.35B
| $147M | 5.44% |
8,256,032
+246,585
| +3% | +$4.41M |
2025 Q2
4 quarters
|
|
2
Hinge Health
HNGE
$8.48B
| $110M | 4.08% |
1,330,127
-124,996
| -9% | -$6.79M |
2025 Q3
3 quarters
|
|
3
Glaukos
GKOS
$9.76B
| $82.7M | 3.06% |
591,927
-171,578
| -22% | -$21.7M |
2022 Q4
14 quarters
|
|
4
Edgewise Therapeutics
EWTX
$3.94B
| $81.1M | 3% |
1,996,965
-350,618
| -15% | -$12.1M |
2024 Q3
7 quarters
|
|
5
Spyre Therapeutics
SYRE
$7.52B
| $78.1M | 2.89% |
879,467
-53,356
| -6% | -$3.89M |
2023 Q4
10 quarters
|
|
6
iRhythm Holdings
IRTC
$3.55B
| $77.8M | 2.88% |
654,262
+44,070
| +7% | +$5.12M |
2022 Q4
14 quarters
|
|
7
NeoGenomics
NEO
$2.14B
| $71.8M | 2.65% |
4,918,202
-699,200
| -12% | -$6.75M |
2025 Q3
3 quarters
|
|
8
Kodiak Sciences
KOD
$5.76B
| $69.6M | 2.58% |
1,787,318
-31,347
| -2% | -$1.22M |
2025 Q4
2 quarters
|
|
9
Xenon Pharmaceuticals
XENE
$3.33B
| $68.3M | 2.53% |
1,131,452
-207,000
| -15% | -$11.5M |
2022 Q4
14 quarters
|
|
10
Monte Rosa Therapeutics
GLUE
$844M
| $59.3M | 2.19% |
2,451,562
-755,012
| -24% | -$14.3M |
2025 Q4
2 quarters
|
|
11
Dianthus Therapeutics
DNTH
$4.34B
| $58M | 2.14% |
594,562
-304,802
| -34% | -$26.6M |
2025 Q3
3 quarters
|
|
|
12
Neurocrine Biosciences
NBIX
$13.7B
| $56.7M | 2.1% |
336,171
-315,950
| -48% | -$46.9M |
2023 Q1
13 quarters
|
|
|
13
Alphatec Holdings
ATEC
$1.67B
| $56.5M | 2.09% |
6,531,439
+4,358,714
| +201% | +$39.7M |
2026 Q1
1 quarter
|
|
14
Generate Biomedicines
GENB
$1.57B
| $55.4M | 2.05% |
3,283,844
-309,155
| -9% | -$4.21M |
2026 Q1
1 quarter
|
|
15
Maravai LifeSciences
MRVI
$973M
| $54.3M | 2.01% |
8,702,921
-1,537,243
| -15% | -$6.64M |
2023 Q2
12 quarters
|
|
16
Krystal Biotech
KRYS
$9.51B
| $47.9M | 1.77% |
128,975
-53,450
| -29% | -$16M |
2022 Q4
14 quarters
|
|
|
17
Humana
HUM
$50.5B
| $45.5M | 1.68% |
+114,500
| New | +$32.6M |
2026 Q2
0 quarters
|
|
18
Thermo Fisher Scientific
TMO
$245B
| $44.8M | 1.66% |
89,395
-3,520
| -4% | -$1.69M |
2024 Q4
6 quarters
|
|
19
Kymera Therapeutics
KYMR
$8.87B
| $43.4M | 1.6% |
378,163
+40,604
| +12% | +$3.49M |
2025 Q3
3 quarters
|
|
20
Rhythm Pharmaceuticals
RYTM
$5.96B
| $42.3M | 1.57% |
381,128
+70,500
| +23% | +$6.37M |
2026 Q1
1 quarter
|
|
|
DMRA
21
Damora Therapeutics
DMRA
$1.15B
| $42.1M | 1.56% |
1,620,377
+725,531
| +81% | +$17.6M |
2026 Q1
1 quarter
|
|
22
Acadia Pharmaceuticals
ACAD
$3.21B
| $41.7M | 1.54% |
1,646,399
-824,800
| -33% | -$18.1M |
2025 Q3
3 quarters
|
|
23
BrightSpring Health Services
BTSG
$12.4B
| $41.6M | 1.54% |
596,753
-419,809
| -41% | -$23.3M |
2025 Q4
2 quarters
|
|
24
Transmedics
TMDX
$2.74B
| $40.5M | 1.5% |
609,715
+280,324
| +85% | +$23.7M |
2024 Q4
6 quarters
|
|
25
MBX Biosciences
MBX
$2.36B
| $39.2M | 1.45% |
710,880
-781,587
| -52% | -$27.3M |
2025 Q4
2 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.